The Report Cardiac Biomarkers Market By
Type (Troponin, Creatine kinase - MB (CK-MB), Natriuretic peptides - B-type
Natriuretic Peptide (BNP) & N-terminal pro b-type Natriuretic peptide
(NT-proBNP), Myoglobin, Ischemia Modified Albumin (IMA), Heart-type Fatty Acid
Binding Protein (H-FABP), LDH isoenzymes), By Application (Acute Coronary
Syndrome, Myocardial infarction, Congestive heart failure, Cardiomyopathy,
Ischemia, Myocarditis, Atrial fibrillation), By End Use, By Region And Segment
Forecasts To 2024
The cardiac biomarkers market is expected
to reach USD13.3 billion by 2024, according to a new report by Grand View
Research, Inc. The cardiac biomarkers market is anticipated to witness a
lucrative growth during the forecast period from 2016 to 2024. Analysis of
global market trends focuses on the increasing demand for cardiac biomarkers
owing to its increased adoption in cardiovascular disease diagnosis.
Furthermore, this growth is attributed to a majority of factors, such as the
high prevalence of Acute Coronary Syndrome (ACS), continual technological
advancements in the development of cardiovascular biomarkers, increasing number
of new product launches by the key market players, rising demand for point of
care cardiac testing kits, along with the high specificity and sensitivity of
these biomarkers in the detection of cardiovascular diseases, especially acute
myocardial infarction.
The
cardiac biomarkers market has been classified by type into troponin, Creatine
kinase-MB(CK-MB), B-type Natriuretic Peptide (BNP), and N-terminal pro b-type
natriuretic peptide (NT-proBNP), myoglobin, and others. Troponin is a
heteromeric protein and comprises cardiac troponin T & I, which are abbreviated
as cTnT & cTnI, respectively. The troponin biomarkers segment is expected
to grow lucratively in the forecast period at a significant CAGR. The
diagnostic efficiency and specificity related to cardiac biomarker testing
renders it a universally gold standard test to diagnose cardiovascular
disorders worldwide. The market by application is segmented into acute coronary
syndrome, myocardial infarction, congestive heart failure, and others. ACS is
expected to be the highest grossing segment according to the study. ACS is
responsible for huge medical costs globally and is responsible for most
hospital readmission cases. The increasing efforts to cut down worldwide ACS
prevalence rates are expected to drive the growth of the biomarkers market.
The
key countries included in the report are U.S., Canada, Germany, UK, China,
India, Brazil, Mexico, South Africa, and the Middle East. North America
accounted for the largest market in 2015, whereas the Asia Pacific region is
anticipated to be the fastest growing region during the forecast period.
Access Research Report of Cardiac Biomarkers Market @ www.grandviewresearch.com/industry-analysis/cardiac-biomarker-market
Further key findings
from the study suggest:
· North America is estimated to dominate the global cardiac
biomarkers market. The high prevalence of coronary heart disease in western
countries is one of the major factors contributing to the high demand for
cardiac biomarker diagnostics.
· The Asia Pacific region is anticipated to be the fastest
growing region in the study period owing to the large population, especially in
China and India. Apart from that, there exists a high prevalence rate of
myocardial infarction in the region. This prevalence rate is expected to fuel
the demand for cardiac biomarker diagnostics.
· The troponin biomarker segment is expected to grow at a
significant rate, and is expected to grow at the highest CAGR compared to
others and accounts for the largest market share in 2015.
· The sector comprises of several local as well as global
players. Some of the major players of this vertical include Alere, Inc.,
Siemens Healthcare GmbH, Roche Diagnostics, Beckman Coulter, Inc., Thermo
Fisher Scientific, Inc., Becton, Dickinson and Company, and bioMerieux SA.
Grand View Research has segmented the cardiac biomarkers
market on the basis of type, application, end use, and region:
Cardiac Biomarkers Type
Outlook (Revenue, USD Million, 2013 - 2024)
·
Troponin
·
CK-MB
·
Natriuretic peptides - BNP and NT-proBNP
·
Myoglobin
·
Others
Cardiac Biomarkers
Market Application Outlook (Revenue, USD Million, 2013 - 2024)
·
Acute Coronary Syndrome
·
Myocardial infarction
·
Congestive heart failure
·
Others
Cardiac Biomarkers
Market End-use Outlook (Revenue, USD Million, 2013 - 2024)
·
Laboratory Testing
·
Point of Care Testing
Cardiac
Biomarkers Regional Outlook (Revenue, USD Million, 2013 - 2024)
·
North America
o U.S.
o Canada
·
Europe
o Germany
o UK
·
Asia Pacific
o China
o India
·
Latin America
o Brazil
o Mexico
·
MEA
o South
Africa
o Middle
East
About Grand View Research
Grand View Research, Inc. is a
U.S. based market research and consulting company, registered in the State of
California and headquartered in San Francisco. The company provides
syndicated research reports, customized research reports, and consulting services.
To help clients make informed business decisions, we offer market intelligence
studies ensuring relevant and fact-based research across a range of industries,
from technology to chemicals, materials and healthcare.
